Sign Up to like & get
recommendations!
1
Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.2548
Abstract: 2548Background: PI3K/mTOR and MAPK pathways are aberrantly activated in many tumours and interact to promote tumour growth and therapeutic resistance. Activity of single pathway inhibition is limit...
read more here.
Keywords:
study vistusertib;
vistusertib combination;
selumetinib patients;
advanced cancers ... See more keywords